
    
      This study consists of arms receiving ASP7517 monotherapy and arms receiving ASP7517 and
      pembrolizumab combination therapy in Phase 1 (dose escalation cohort) and Phase 2 (dose
      expansion cohort).

      Phase 1 (Dose Escalation Cohort):

      The first dose in the combination therapy arm will begin after completing the first dose in
      the monotherapy arm.

      Phase 2 (Dose Expansion Cohort):

      Phase 2 monotherapy and combination dose expansion cohorts will be opened after the phase 1
      escalation cohort has been completed.
    
  